rosiglitazone has been researched along with 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bibli, SI; Chaikuad, A; Fischer-Posovszky, P; Fleming, I; Hartmann, M; Heering, J; Hernandez-Olmos, V; Kilu, W; Kircher, T; Knapp, S; Krait, S; Kramer, JS; Merk, D; Ni, X; Proschak, E; Scriba, GKE; Tews, D; Weizel, L | 1 |
1 other study(ies) available for rosiglitazone and 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
| Article | Year |
|---|---|
Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARĪ³ Modulator.
Topics: Adipocytes; Animals; Benzamides; Butyrates; Cardiotonic Agents; Cell Differentiation; Enzyme Inhibitors; Epoxide Hydrolases; HEK293 Cells; Humans; Mice, Inbred C57BL; PPAR gamma; Stereoisomerism | 2021 |